Is ticagrelor worth its high cost and side-effects? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Acta Cardiologica Année : 2019

Is ticagrelor worth its high cost and side-effects?

(1) , , (2) , , (1)
1
2

Résumé

Ticagrelor is a reversible P2Y(12) receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y(12) receptor antagonist, with a loading dose.
Fichier non déposé

Dates et versions

hal-03583843 , version 1 (22-02-2022)

Identifiants

Citer

Raphaelle-Ashley Guerbaai, Indrajeet Mahata, Sylvestre Marechaux, Thierry H. Le Jemtel, Pierre-Vladimir Ennezat. Is ticagrelor worth its high cost and side-effects?. Acta Cardiologica, 2019, 74 (2), pp.93-98. ⟨10.1080/00015385.2018.1469371⟩. ⟨hal-03583843⟩

Collections

U-PICARDIE MP3CV
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More